# A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study

> **NCT03355820** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 228 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia

## Interventions

- **PROCEDURE:** Blood sampling for antibody determination

## Key facts

- **NCT ID:** NCT03355820
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-28
- **Primary completion:** 2018-06-29
- **Final completion:** 2018-06-29
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2020-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03355820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03355820, "A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03355820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*